Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Axis Genetics and Biomira collaborate on the development of a cancer vaccine

Nov. 16, 1998

AltaRex seeks permission to study immunological activity of OvaRex in phase II trial

Nov. 11, 1998

AltaRex moves to conduct clinical trial with OvaRex in more advanced ovarian cancer

Nov. 6, 1998

Adoptive immunotherapy of cancer with HSPs covered by U.S. patent

Nov. 4, 1998

Ribi ImmunoChem withdraws European Melacine application; focuses on U.S. and Canada

Nov. 3, 1998

FDA okays U.S. portion of multinational study evaluating Theratope

Nov. 2, 1998

Genentech begins shipping Herceptin to U.S. oncologists

Oct. 30, 1998

Positive initial clinical findings reported for first-generation GVAX vaccine for melanoma

Oct. 29, 1998

Positive efficacy and safety results reported for IDEC-Y2B8/Rituxan in NHL

Oct. 29, 1998

Japanese patent allowed for Maxamine technology

Oct. 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...